Use of Peptides for the Management of Alzheimer’s Disease: Diagnosis and Inhibition

Frontiers in Aging Neuroscience

Khurshid Ahmad¹  Gulam Rabbani¹  Mohammad H. Baig¹  Inho Choi¹ 

[1] epartment of Medical Biotechnology, Yeungnam University, Gyeongsan, South Korea;

关键词: Alzheimer’s disease;    peptides;    amyloid beta;    BACE-1;    GAPDH;    inhibitors;   

DOI  :  10.3389/fnagi.2018.00021

来源: DOAJ

【 摘 要 】

Alzheimer’s disease (AD) is a form of dementia and the most common progressive neurodegenerative disease (ND). The targeting of amyloid-beta (Aβ) aggregation is one of the most widely used strategies to manage AD, and efforts are being made globally to develop peptide-based compounds for the early diagnosis and treatment of AD. Here, we briefly discuss the use of peptide-based compounds for the early diagnosis and treatment of AD and the use of peptide-based inhibitors targeting various Aβ aggregation checkpoints. In addition, we briefly discuss recent applications of peptide-based inhibitors against various AD targets including amyloid beta, β-site amyloid precursor protein cleaving enzyme 1 (BACE1), Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), tyrosine phosphatase (TP) and potassium channel KV1.3.

【 授权许可】

Unknown